The Penn Blood Disorders Center conducts cutting-edge clinical research in non-malignant blood disorders including, but not limited to:
- Autoimmune hemolytic anemia
- Heparin-induced thrombocytopenia
- Immune thrombocytopenia (ITP)
- Sickle cell disease
- Thrombotic thrombocytopenic purpura (TTP)
- Venous thromboembolism
- Von Willebrand disease
At any one time, there are approximately 30 research studies open for enrollment. These include observational studies as well as clinical trials of new drugs and treatments.
Some recent highlights of our research program include participation in gene therapy studies for hemophilia and in a clinical trial that led to FDA approval of a new treatment for thalassemia.
Our patients have the opportunity to participate in this innovative research. In 2019 alone, 482 of our patients enrolled in research studies.